Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade | Zendy

Tala Shekarian | Zendy; Éva Sivadó | Zendy; Anne-Catherine Jallas | Zendy; Stéphane Depil | Zendy; Janice Kielbassa | Zendy; Isabelle JanoueixLerosey | Zendy; Gregor Hütter | Zendy; Nadège Goutagny | Zendy; Christophe Bergeron | Zendy; Alain Viari | Zendy; Sandrine ValsesiaWittmann | Zendy; Christophe Caux | Zendy; Aurélien Marabelle | Zendy

AI Assistant Blog Pricing

Open Access

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

Author(s) -

Tala Shekarian,

Éva Sivadó,

Anne-Catherine Jallas,

Stéphane Depil,

Janice Kielbassa,

Isabelle JanoueixLerosey,

Gregor Hütter,

Nadège Goutagny,

Christophe Bergeron,

Alain Viari,

Sandrine ValsesiaWittmann,

Christophe Caux,

Aurélien Marabelle

Publication year - 2019

Publication title -

science translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.819

H-Index - 216

eISSN - 1946-6242

pISSN - 1946-6234

DOI - 10.1126/scitranslmed.aat5025

Subject(s) - oncolytic virus , immune system , medicine , immunotherapy , immune checkpoint , rotavirus , immunology , immunogenicity , cancer research , virology , virus

Rotavirus vaccines have oncolytic properties and can overcome resistance to anti–PD-(L)1/CTLA-4 via RIG-I activation upon intratumoral administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog